Advertisement
Akebia Therapeutics Resubmits NDA For Vadadustat To FDA
(RTTNews) - Biopharmaceutical company Akebia Therapeutics, Inc. (AKBA) announced Thursday it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is currently approved for use in 35 countries.
Based on standard NDA resubmission review timelines, a letter from the FDA acknowledging that the resubmission is complete, classifying the resubmission, and setting the PDUFA date is expected in 30 days. Akebia expects the FDA to set a PDUFA date of six months from the date of submission.
For More Such Health News, visit rttnews.com
read more
Akebia Therapeutics Expects To Resubmit NDA For Vadadustat NDA In Q3
Biopharmaceutical company Akebia Therapeutics, Inc. (AKBA) announced Thursday that the company expects to resubmit its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on dialysis by the end of the third quarter of 2023.
RTTNews
|
713 ngày trước
Canadian Stocks Surge Higher Again; TSX Scales New Record High
Canadian stocks are up firmly in positive territory on Wednesday, and the benchmark S&P/TSX Composite Index stays high up after hitting a fresh record. Rising optimism about a rate cut by the Federal Reserve in September, firm oil prices and some upbeat corporate earnings announcements are contributing to the positive mood in the market.
RTTNews
|
46 phút trước
India Holds Key Interest Rates Steady As Trade Tensions Escalate
The Reserve Bank of India left its key interest rates unchanged on Wednesday after an aggressive cut in June as the economy faces another threat from the US due to its Russian oil imports. The RBI Monetary Policy Committee, led by Governor Sanjay Malhotra, unanimously decided to hold the policy repo rate at 5.50 percent. The bank had reduced the rate by 50 basis points in June.
RTTNews
|
3h 18phút trước
Bay Street Looks Set To Extend Upmove
Canadian shares look headed for a positive start on Wednesday, riding on some impressive corporate earnings updates, and higher oil prices. The focus will also be on the developments on the trade front.
RTTNews
|
4h 46phút trước
Eurozone Retail Sales Recover In June
Euro area retail sales rebounded in June suggesting that household spending likely supported economic growth in the second quarter, official data revealed on Wednesday. Retail sales grew 0.3 percent on a monthly basis in June, offsetting May's 0.3 percent decline, Eurostat said. However, this was marginally weaker than economists' forecast for a 0.4 percent increase.
RTTNews
|
4h 56phút trước
Euro Rises As European Shares Traded Higher
The euro strengthened against other major currencies in the European session on Wednesday, as European shares traded higher despite weak factory orders data from Germany and fresh tariff threats from U.S. President Donald Trump on pharma and chips. Some upbeat earnings announcements and expectations of a Fed interest rate cut next month appear to be aiding sentiment.
RTTNews
|
5h 29phút trước
Disney Lifts FY25 EPS View After Q3 Profit Beats Market; ESPN In Deal With WWE, NFL
Media and entertainment major Walt Disney Co. (DIS) on Wednesday raised fiscal 2025 outlook for earnings.above the Street after reporting significantly higher profit in its third quarter, above market estimates. Meanwhile, revenues missed the market view, despite reporting a growth. Separately, Disney announced that its unit ESPN has signed a landmark rights agreement with WWE.
RTTNews
|
5h 46phút trước
Dynatrace Boosts FY26 Outlook - Update
While reporting financial results for the first quarter on Wednesday, software intelligence provider Dynatrace, Inc. (DT) provided its adjusted earnings and revenue guidance for the second quarter and raised its outlook for the full-year 2026.
RTTNews
|
5h 52phút trước
